Anapol Weiss is currently investigating cases on behalf of individuals who took Dupixent (also known by its generic name, dupilumab) and thereafter were diagnosed with Cutaneous T‑Cell Lymphoma (CTCL) skin cancer.
Dupixent is an anti-inflammatory medication most commonly prescribed to individuals with moderate to severe atopic dermatitis (AD). Peer-reviewed studies report a significantly elevated risk of CTCL among patients treated with Dupixent/dupilumab. Common symptoms of CTCL include dry and red scaly patches or bumps on your skin. Additional symptoms can include rashes, lumps and tumors, discoloration, thickened skin, swollen lymph nodes, hair loss, itching, fever and chills, unexplained weight loss, pain or tenderness, and night sweats.
If you or a loved one were prescribed Dupixent and were diagnosed with CTCL skin cancer, Anapol Weiss may be able to help you. Please contact us for a free consultation.